Yahoo Finance • last year
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive... Full story
Yahoo Finance • last year
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • last year
AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • last year
AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • last year
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • last year
Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5 following standard safety review Updates on the ReSPECT-LM trial and on the ReSPECT-GBM tri... Full story
Yahoo Finance • last year
Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between t... Full story
Yahoo Finance • last year
CNSide™ assay is the gold standard diagnostic cerebrospinal fluid (CSF) assay for patients with suspected central nervous system (CNS) cancers As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for pa... Full story
Yahoo Finance • last year
AUSTIN, Texas, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervo... Full story
Yahoo Finance • last year
ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial Management to host conf... Full story
Yahoo Finance • last year
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • last year
ReSPECT-GBM Phase 1 recurrent glioblastomatrial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial demonstrates safety and high absorbed radiation do... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervou... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous... Full story
Yahoo Finance • 2 years ago
New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PS... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervo... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervo... Full story
Yahoo Finance • 2 years ago
The Company plans to meet with U.S. FDA to discuss next steps for the Phase 1/Part B trial in the third quarter of 2023 Expanded the number of active clinical trial sites by adding Northwestern Memorial Hospital, a world-class medical cen... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers,... Full story